Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer: a multicentre randomised controlled trial

Trial Profile

Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer: a multicentre randomised controlled trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
  • Focus Therapeutic Use

Most Recent Events

  • 29 Apr 2021 Results of pooled analysis from three clinical studies: CONKO-001, CONKO-005, and CONKO-006 published in the European Journal of Cancer
  • 31 May 2020 Results of a pooled analysis from four phase III trials: CONKO-001, JASPAC-01, ESPAC-4 and PRODIGE assessing prolongation of average survival time, prolongation of average event free time and time lived without an event presented at the 56th Annual Meeting of the American Society of Clinical Oncology
  • 31 Mar 2020 Results published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top